Alnylam Pharmaceuticals
ALNY
#649
Rank
S$41.43 B
Marketcap
$321.22
Share price
-7.14%
Change (1 day)
40.05%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.51. In 2022 the company made an earnings per share (EPS) of -$12.46 a decrease over its 2021 EPS that were of -$9.66.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-55.89%
2022-$12.4629.03%
2021-$9.66-3.36%
2020-$9.99-8.48%
2019-$10.927.67%
2018-$10.1439.74%
2017-$7.2612.94%
2016-$6.4238.84%
2015-$4.63-32.88%
2014-$6.89259.44%
2013-$1.92-31.25%
2012-$2.7952.94%
2011-$1.8230.77%
2010-$1.39-8.77%
2009-$1.5378.13%
2008-$0.86-70.78%
2007-$2.9499.09%
2006-$1.48-43.88%
2005-$2.63-82.33%
2004-$14.88-59.23%
2003-$36.49

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.28-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$50.11-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.50 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.36-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.27-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.02-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.27-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.68-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel